The U.S. Food and Drug Administration has officially confirmed a nationwide shortage of estradiol transdermal patches, signaling that federal regulators are coordinating with manufacturers to boost production. The agency released a statement earlier this month acknowledging the supply constraints affecting patients across Idaho and the broader nation.
Estradiol patches deliver estrogen through the skin to replace hormones lost during menopause, a biological transition typically occurring between ages 45 and 55 according to the National Institute on Aging. These treatments help manage common symptoms including hot flashes, night sweats, insomnia, and bone density loss.
All six manufacturers producing these patches are currently working to expand their production capacity and prioritize output for this medication class. The FDA noted that rising interest in menopause treatment represents an important development for women’s health, stating the agency is “working closely with manufacturers to help ensure that the supply of estradiol patches keeps pace with demand.”
This marks the first time the federal regulator has listed these specific patches on its official shortage inventory. The FDA had not included them in its shortage list as recently as May. However, the American Society of Health-System Pharmacists identified supply issues as early as January.
The timing of the shortage follows a regulatory shift by the FDA, which removed estradiol patches from “black box” warning status two months before pharmacists first flagged the scarcity. Removing such warnings often leads to increased prescribing and patient demand.
Legislative activity surrounding menopause care has accelerated significantly in recent years. As of May, more than 60 pieces of menopause-related legislation had been introduced nationwide. Since 2019, twenty-six states have enacted laws addressing menopause care, with additional bills expected during the upcoming 2027 legislative sessions.
For Idaho residents relying on hormone replacement therapy, the shortage may result in temporary difficulties obtaining prescriptions. Patients experiencing symptoms should consult their healthcare providers about alternative treatment options while supply chains stabilize. The FDA continues to monitor manufacturing updates and will adjust its shortage list as production levels change.